ORM-5029 is under clinical development by Orum Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ORM-5029’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORM-5029 is under development for the treatment of solid tumor and HER2-expressing breast cancer such as HER2+ breast cancer, gastric or gastroesophageal junction adenocarcinoma or tumors with HER2 expression, amplification or mutations (e.g., colorectal, bile duct, ovarian, bladder, non-small cell lung). It is an antibody neoDegrader conjugate (AnDC) and being developed based on OromabTM, a cell-specific, cell-penetrating antibody platform technology. It is administered through intravenous route. It acts by targeting HER2 and HER3.
Orum Therapeutics overview
Orum Therapeutics, Inc., a biotechnology company that develops a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer. The company is headquartered in Republic of Korea (South Korea).
For a complete picture of ORM-5029’s drug-specific PTSR and LoA scores, buy the report here.